Skip to main content
OpenTrials
Completed

NCT Number: NCT04345887

Spironolactone in Covid-19 Induced ARDS

This study intended to evaluate the effects of commonly used diuretic, spironolactone, on oxygenation in covid-19 ARDS patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Respiratory Distress Syndrome, Adult Lung Diseases Respiration Disorders Respiratory Distress Syndrome Respiratory Tract Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Istanbul University-Cerrahpaşa

Istanbul, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hemodynamically stable
  • Hypoxemia, i.e. p/f <150
  • Admitted to ICU within 48 hours
  • Not moribund has a life expectancy greater than 24 hours

Exclusion criteria

  • Age criteria
  • Pregnancy
  • Unwillingness to participate

Treatment and study plan

Spironolactone 100mg

Drug

2x100 mg spironolactone for 5 consecutive days

Placebo oral tablet

Drug

2 x1 placebo tablet

Primary outcomes

  1. p/f ratio

    Time frame: 5 days

    improvement in oxygenation

Secondary outcomes

  1. SOFA

    Time frame: 5 days

    improvement in SOFA Score

Sponsors and collaborators

Lead sponsor

Istanbul University - Cerrahpasa

Other

Registry information

Official study title

The Effect of Spironolactone on Oxygenation in Covid-19 ARDS Patients

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Apr 15, 2020
Registry last updated
Oct 28, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.